Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 58.5% in October

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,230,000 shares, an increase of 58.5% from the October 15th total of 776,000 shares. Based on an average trading volume of 618,200 shares, the short-interest ratio is presently 2.0 days. Approximately 3.8% of the shares of the company are sold short.

Werewolf Therapeutics Stock Performance

Shares of HOWL opened at $1.77 on Friday. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. The firm has a market cap of $78.88 million, a PE ratio of -1.16 and a beta of 0.41. The company’s 50 day simple moving average is $2.27 and its 200-day simple moving average is $2.88. Werewolf Therapeutics has a 12-month low of $1.66 and a 12-month high of $8.19.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new position in Werewolf Therapeutics in the 3rd quarter valued at $29,000. Point72 DIFC Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at about $34,000. XTX Topco Ltd acquired a new position in Werewolf Therapeutics in the 3rd quarter valued at about $45,000. Rhumbline Advisers acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at about $79,000. Finally, American Century Companies Inc. grew its holdings in Werewolf Therapeutics by 50.7% in the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after buying an additional 12,656 shares during the period. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.